AstraZeneca PLC (AZN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $286.07B
Last updated: Nov 17, 2026 at 11:05 AM ET
AstraZeneca PLC (AZN) Stock Forecast
Analysts expect AstraZeneca (AZN) to earn $10.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $63.38B. Of 12 analysts, 9 rate the stock Buy or Strong Buy, 2 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 7 | 58.3% |
| Hold | 2 | 16.7% |
| Sell | 1 | 8.3% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 11.9% and revenue estimates rise 6.3%.
- Fiscal year ending Dec 31, 2026
- $10.12
- EPS consensus, revenue $63.38B
- Fiscal year ending Dec 31, 2027
- $11.32
- EPS consensus, revenue $67.39B
- Fiscal year ending Dec 31, 2028
- $12.95
- EPS consensus, revenue $72.12B
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $10.12 | $10.08 to $10.16 | 2 | $63.38B | $61.91B to $64.21B | 25 |
| Dec 31, 2027 | $11.32 | $10.83 to $11.84 | 3 | $67.39B | $65.24B to $68.92B | 25 |
| Dec 31, 2028 | $12.95 | $9.56 to $14.40 | 9 | $72.12B | $71.84B to $72.41B | 21 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.43 | $2.09 to $2.72 | 18 | $17.18B | $15.82B to $18.21B | 19 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.3% from $10.09.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $10.12 | $10.05 | $10.07 | $10.05 | $10.09 | +0.3% |
| Fiscal year ending Dec 31, 2027 | $11.32 | $11.34 | $11.57 | $11.36 | $11.58 | -2.3% |
Frequently Asked Questions About AZN
What is the AZN stock forecast?
Consensus analyst estimates put AstraZeneca's EPS at $10.12 for the fiscal year ending Dec 31, 2026, on revenue of $63.38B. The consensus rating from 12 analysts is Buy.
How do analysts rate AZN stock?
Of 12 analysts covering AstraZeneca, 2 rate it Strong Buy, 7 Buy, 2 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AZN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $10.12, with estimates from $10.08 to $10.16 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.32, with estimates from $10.83 to $11.84 from 3 analysts.
What revenue do analysts expect from AstraZeneca next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $63.38B, with estimates from $61.91B to $64.21B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $67.39B, with estimates from $65.24B to $68.92B.
How many analysts cover AZN?
12 analysts rate AstraZeneca stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AZN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts